WO2005016326A3 - Analogs of thalidomide as potential angiogenesis inhibitors - Google Patents

Analogs of thalidomide as potential angiogenesis inhibitors Download PDF

Info

Publication number
WO2005016326A3
WO2005016326A3 PCT/US2004/022242 US2004022242W WO2005016326A3 WO 2005016326 A3 WO2005016326 A3 WO 2005016326A3 US 2004022242 W US2004022242 W US 2004022242W WO 2005016326 A3 WO2005016326 A3 WO 2005016326A3
Authority
WO
WIPO (PCT)
Prior art keywords
thalidomide
analogs
angiogenesis inhibitors
potential angiogenesis
subject
Prior art date
Application number
PCT/US2004/022242
Other languages
French (fr)
Other versions
WO2005016326A2 (en
Inventor
William D Figg
Frederick Luzzio
Kurt Eger
Michael Weiss
Sunna Hauschildt
Thomas Hecker
Erin R Lepper
Original Assignee
Us Gov Health & Human Serv
William D Figg
Frederick Luzzio
Kurt Eger
Michael Weiss
Sunna Hauschildt
Thomas Hecker
Erin R Lepper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, William D Figg, Frederick Luzzio, Kurt Eger, Michael Weiss, Sunna Hauschildt, Thomas Hecker, Erin R Lepper filed Critical Us Gov Health & Human Serv
Publication of WO2005016326A2 publication Critical patent/WO2005016326A2/en
Publication of WO2005016326A3 publication Critical patent/WO2005016326A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Methods of inhibiting angiogenesis that include administering to a subject a therapeutically effective amount of at least one select thalidomide analog or pharmaceutically acceptable salts thereof. According to one aspect, the select compounds are administered for treating a tumor in a subject.
PCT/US2004/022242 2003-07-11 2004-07-09 Analogs of thalidomide as potential angiogenesis inhibitors WO2005016326A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48651503P 2003-07-11 2003-07-11
US60/486,515 2003-07-11

Publications (2)

Publication Number Publication Date
WO2005016326A2 WO2005016326A2 (en) 2005-02-24
WO2005016326A3 true WO2005016326A3 (en) 2005-06-16

Family

ID=34193060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/022242 WO2005016326A2 (en) 2003-07-11 2004-07-09 Analogs of thalidomide as potential angiogenesis inhibitors

Country Status (1)

Country Link
WO (1) WO2005016326A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
SG133603A1 (en) 2003-09-17 2007-07-30 Us Gov Health & Human Serv Thalidomide analogs as tnf-alpha modulators
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
CA2648216C (en) 2006-04-13 2016-06-07 Michael Gutschow Tetrahalogenated compounds useful as inhibitors of angiogenesis
WO2008007979A1 (en) * 2006-07-12 2008-01-17 Auckland Uniservices Limited (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
CN103221039A (en) 2010-09-09 2013-07-24 三叶草私人有限公司 Airway administration of angiogenesis inhibitors
ES2617446T3 (en) 2010-09-27 2017-06-19 Morphosys Ag Anti-cd38 and lenalidomide or bortezomib antibody for the treatment of multiple myeloma and nhl
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
JP6815318B2 (en) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド How to Induce Targeted Proteolysis by Bifunctional Molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA3010796A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
CA3017740A1 (en) 2016-03-16 2017-09-21 Pearlie BURNETTE Small molecules against cereblon to enhance effector t cell function
EA201892542A1 (en) 2016-05-30 2019-06-28 МорфоСис АГ METHODS OF FORECASTING IN PATIENTS OF THERAPEUTIC EFFECT OF THERAPY THERAPY USING ANTIBODIES TO CD19
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
CN106806366B (en) * 2016-12-29 2020-02-11 兰州大学 New application of isoindole-1, 3-diketone compound
US20200199097A1 (en) * 2017-08-21 2020-06-25 Nanjing Noratech Pharmaceuticals Co., Ltd Pomalidomide derivative and preparation method therefor
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CN107698648B (en) * 2017-08-30 2020-08-14 大连理工大学 Naphthylimide derivative containing cholesterol and synthesis and application thereof
PE20210184A1 (en) 2018-07-11 2021-02-02 H Lee Moffitt Cancer Ct & Res DIMERIC IMMUNOMODULATOR COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS
WO2020023782A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
CN111499610A (en) * 2019-01-31 2020-08-07 南京诺瑞特医药科技有限公司 Polymorphs of pomalidomide prodrug salt
JP2022532519A (en) 2019-05-03 2022-07-15 モルフォシス・アーゲー Anti-CD19 therapy in patients with a limited number of NK cells
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
JP2023501211A (en) 2019-10-31 2023-01-18 モルフォシス・アーゲー Sequential anti-CD19 treatment
JP2023501209A (en) 2019-10-31 2023-01-18 モルフォシス・アーゲー Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
EP3915556A1 (en) 2020-05-27 2021-12-01 Franz Josef Vonnahme Rectal application of thalidomide in patients with hemorrhagic chronic radiation proctitis
CN113912589B (en) * 2020-07-08 2023-10-20 北京泰德制药股份有限公司 Compounds that inhibit and induce protein degradation
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB962857A (en) * 1961-12-04 1964-07-08 Distillers Co Yeast Ltd Process for the production of imides
US3314953A (en) * 1964-03-16 1967-04-18 Richardson Merrell Inc 1-substituted-3-phthalimido-2, 5-dioxopyrrolidines
GB1075420A (en) * 1965-05-08 1967-07-12 Gruenenthal Chemie Cyclic imide compounds and a process for their production
US3560495A (en) * 1965-05-08 1971-02-02 Ernst Frankus 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6
US4092147A (en) * 1975-11-12 1978-05-30 American Cyanamid Company Method for controlling the relative stem growth of plants
US4291048A (en) * 1978-07-06 1981-09-22 Joseph Gold Method of treating tumors and cancerous cachexia with L-tryptophan
DE3332633A1 (en) * 1983-09-09 1985-04-04 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Substituted carboxylic acid derivatives, process for their preparation, and pharmaceuticals
WO1994020085A1 (en) * 1993-03-01 1994-09-15 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
WO1997012625A1 (en) * 1995-10-03 1997-04-10 Cytran, Ltd. Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
WO1997037988A1 (en) * 1996-04-09 1997-10-16 Grünenthal GmbH Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
WO1998025895A1 (en) * 1996-12-13 1998-06-18 Eli Lilly And Company Inhibitors of the enzymatic activity of psa
US5783605A (en) * 1995-02-27 1998-07-21 Kuo; Sheng-Chu Helper inducers for differentiation therapy and chemoprevention of cancer
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
WO1999013873A1 (en) * 1997-09-15 1999-03-25 Klavdia Stepanovna Evlanenkova Agent for treating patients suffering from tumours
WO2002064083A2 (en) * 2000-11-30 2002-08-22 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
WO2003014315A2 (en) * 2001-08-06 2003-02-20 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
WO2003097052A2 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2004085422A1 (en) * 2003-03-27 2004-10-07 Tian Jin Hemay Bio-Tech Co., Ltd. Water-soluble thalidomine derivatives

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB962857A (en) * 1961-12-04 1964-07-08 Distillers Co Yeast Ltd Process for the production of imides
US3314953A (en) * 1964-03-16 1967-04-18 Richardson Merrell Inc 1-substituted-3-phthalimido-2, 5-dioxopyrrolidines
GB1075420A (en) * 1965-05-08 1967-07-12 Gruenenthal Chemie Cyclic imide compounds and a process for their production
US3560495A (en) * 1965-05-08 1971-02-02 Ernst Frankus 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6
US4092147A (en) * 1975-11-12 1978-05-30 American Cyanamid Company Method for controlling the relative stem growth of plants
US4291048A (en) * 1978-07-06 1981-09-22 Joseph Gold Method of treating tumors and cancerous cachexia with L-tryptophan
DE3332633A1 (en) * 1983-09-09 1985-04-04 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Substituted carboxylic acid derivatives, process for their preparation, and pharmaceuticals
WO1994020085A1 (en) * 1993-03-01 1994-09-15 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5783605A (en) * 1995-02-27 1998-07-21 Kuo; Sheng-Chu Helper inducers for differentiation therapy and chemoprevention of cancer
WO1997012625A1 (en) * 1995-10-03 1997-04-10 Cytran, Ltd. Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
WO1997037988A1 (en) * 1996-04-09 1997-10-16 Grünenthal GmbH Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
WO1998025895A1 (en) * 1996-12-13 1998-06-18 Eli Lilly And Company Inhibitors of the enzymatic activity of psa
WO1999013873A1 (en) * 1997-09-15 1999-03-25 Klavdia Stepanovna Evlanenkova Agent for treating patients suffering from tumours
WO2002064083A2 (en) * 2000-11-30 2002-08-22 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
WO2003014315A2 (en) * 2001-08-06 2003-02-20 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
WO2003097052A2 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2004085422A1 (en) * 2003-03-27 2004-10-07 Tian Jin Hemay Bio-Tech Co., Ltd. Water-soluble thalidomine derivatives

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"THE MERCK INDEX", 2001, MERCK & CO., XP002322662 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 October 2004 (2004-10-07), ZHANG, HESHENG: "Preparation of water-soluble thalidomide derivatives", XP002308491, retrieved from STN Database accession no. 2004:817880 *
DATABASE WPI Section Ch Week 199919, Derwent World Patents Index; Class B02, AN 1998-592576 *
DATABASE WPI Section Ch Week 200470, Derwent World Patents Index; Class B02, AN 2004-719020 *
DE A U ET AL: "POSSIBLE ANTINEOPLASTIC AGENTS: III SYNTHESIS OF 6-ALKYL-2- U4'METHOXYPHTHALIMIDO AND 6-ALKYL-3-U3'-4'-DIMETHOXYPHENYL GLUTARIMIDES", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, THE INDIAN CHEMICAL SOCIETY, CALCUTTA, IN, vol. 53, no. 11, 1 November 1976 (1976-11-01), pages 1122 - 1125, XP000675187, ISSN: 0019-4522 *
DE A U ET AL: "POSSIBLE ANTINEOPLASTIC AGENTS: PART IV - SYNTHESIS & ANTINEOPLASTIC POTENCY OF N-SUBSTITUTED ALPHA-(4,5-DIMETHOXYPHTHALIMIDO)GLUTARIMIDES & N-SUBSTITUTED BETA-(4-BROMOPHENYL)GLUTARIMIDES", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC, INCL. MEDICINAL, PUBLICATIONS & INFORMATIONS DIRECTORATE, NEW DELHI, IN, vol. 16B, no. 6, 1 June 1978 (1978-06-01), pages 510 - 512, XP000675183, ISSN: 0019-5103 *
FOLKES L K ET AL: "Oxidative activation of indole-3-acetic acids to cytotoxic species- a potential new role for plant auxins in cancer therapy.", BIOCHEMICAL PHARMACOLOGY. 15 JAN 2001, vol. 61, no. 2, 15 January 2001 (2001-01-15), pages 129 - 136, XP008044869, ISSN: 0006-2952 *
HESS, S. ET AL: "Synthesis and immunological activity of water-soluble thalidomide prodrugs", BIOORGANIC & MEDICINAL CHEMISTRY , 9(5), 1279-1291 CODEN: BMECEP; ISSN: 0968-0896, 2001, XP001202654 *
KARBOWNIK M ET AL: "Indole-3-propionic acid, a melatonin-related molecule, protects hepatic microsomal membranes from iron-induced oxidative damage: relevance to cancer reduction.", JOURNAL OF CELLULAR BIOCHEMISTRY. 2001, vol. 81, no. 3, 2001, pages 507 - 513, XP008044870, ISSN: 0730-2312 *
LENTZSCH S ET AL: "S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 62, 15 April 2002 (2002-04-15), pages 2300 - 2305, XP002959459, ISSN: 0008-5472 *
LEPPER, ERIN R. ET AL: "Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY , 47(9), 2219-2227 CODEN: JMCMAR; ISSN: 0022-2623, 2004, XP001202667 *
NG, SYLVIA S. W. ET AL: "Antiangiogenic Activity of N-substituted and Tetrafluorinated Thalidomide Analogues", CANCER RESEARCH , 63(12), 3189-3194 CODEN: CNREA8; ISSN: 0008-5472, 15 June 2003 (2003-06-15), XP001202664 *
SEDLAK M ET AL: "Preparation, 1H and 13C NMR spectra of substituted 2-benzoylaminocarboxamides", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, ACADEMIC PRESS, LONDON, GB, vol. 60, 1995, pages 150 - 160, XP002136842, ISSN: 0010-0765 *
SUZUKI, MAMORU ET AL: "Use of a new protecting group in an attempted synthesis of cyclopropyldihydroxyphenylalanine", JOURNAL OF ORGANIC CHEMISTRY , 48(24), 4769-71 CODEN: JOCEAH; ISSN: 0022-3263, 1983, XP008044808 *

Also Published As

Publication number Publication date
WO2005016326A2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
WO2005016326A3 (en) Analogs of thalidomide as potential angiogenesis inhibitors
DE60329001D1 (en) 8-hydroxychinolinderivate
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
HK1120441A1 (en) Drugs for treatment of ovarian cancer
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2008064107A3 (en) 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods
DOP2005000039A (en) HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
WO2005002582A3 (en) Trp-p8 active compounds and therapeutic treatment methods
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008151288A3 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2013085849A3 (en) Sulfate esters of noribogaine
WO2006068796A3 (en) Inhibitors of akt activity
MX2022004197A (en) Oral complement factor d inhibitors.
CR20220196A (en) Oral complement factor d inhibitors
WO2006079077A3 (en) Use of diltiazem or analogs thereof as modulators of ghrelin receptor
MX2021002878A (en) Cd73 inhibitors and pharmaceutical uses thereof.
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
WO2005113011A3 (en) Prodrugs of ion channel modulating compounds and uses thereof
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase